GPRC5D-Targeted Therapies in Relapsed Multiple Myeloma

Data support the addition of daratumumab to standard lenalidomide maintenance in patients with newly diagnosed multiple myeloma following transplant.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Data from a phase 1b/2 trial show that sonrotoclax/dexamethasone appears to be well tolerated in a heavily pretreated multiple myeloma population.

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

Nearly all patients in the per-protocol population of the MIDAS study achieved a very good partial response or better following study treatment.

Phase 3 data support a daratumumab-based quadruplet as a new potential regimen in transplant-ineligible newly diagnosed multiple myeloma.